* Dyadic International Inc reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -6 cents. The mean expectation of two analysts for the quarter was for a loss of 7 cents per share.

* Revenue rose 392.9% to $1.96 million from a year ago; analysts expected $1.10 million.

* Dyadic International Inc's reported EPS for the quarter was a loss of 1 cent​.

* The company reported a quarterly loss of $203 thousand.

* Dyadic International Inc shares had risen by 1.0% this quarter and lost 34.8% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 7.7% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Dyadic International Inc is $6.00 This summary was machine generated from LSEG data November 12 at 11:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.07 -0.01 Beat

Jun. 30 2024 -0.06 -0.07 Missed

-0.07

Dec. 31 2023 -0.06 -0.08 Missed